Malcolm Brenner, an internationally recognized physician-scientist known for his leadership in cell and gene therapy, has been named director of the newly created Houston Methodist Cell and Gene Therapy Center.
The center will bring together scientists and clinicians from Houston Methodist’s academic research and clinical care settings to discover and advance new treatments for a wide range of diseases. Its collaborative approach integrates expertise across disciplines and accelerates the translation of promising preclinical discoveries into clinical evaluation. The center will also support the development of both gene and cell therapies designed to address congenital and acquired diseases throughout the body.
Malcom Brenner is a pioneer in the field of cell and gene therapy and is uniquely qualified to lead Houston Methodist’s research efforts in this field. His vision and leadership will play a vital role in advancing our efforts in this area. ”
Jenny Zhang, President and CEO, Houston Methodist Academic Institute
In addition to Brenner, the center will house a team of translational research scientists, physician-scientists, and support staff. Brenner and his team will continue their long-term collaboration at Baylor College of Medicine and Texas Children’s Hospital.
Brenner, a professor of pediatrics, medicine, molecular genetics, human genetics, and translational biology at Baylor College of Medicine, is known for his fundamental contributions to cell and gene therapy as viable clinical treatments. A physician-scientist trained in immunology and hematology, he helped redefine bone marrow transplantation as a form of cell therapy and was one of the first to show that engineered immune cells could safely and effectively treat infectious diseases and cancer. His research established the clinical potential of virus-specific T cells and genetically modified hematopoietic stem cells and laid the foundation for treatments that provide lasting, even lifelong benefits to patients.
Beyond his scientific discoveries, Brenner has played a key role in shaping the global infrastructure for cell and gene therapy research. A leader in major scientific societies and an early standard-setter in the field, he helped guide how these complex treatments are developed, regulated, and delivered. Mr. Brenner was elected to the National Academy of Medicine and the National Academy of Inventors, and has received numerous honors in recognition of his scientific influence and leadership. He received his medical degree and doctorate from the University of Cambridge, UK.
